Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of the American Academy of Dermatology|September 21, 2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsMark Lebwohl, Craig Leonardi, Christopher E M Griffiths, et al.Journal of Drugs in Dermatology : JDD|March 8, 2012
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-upKristian Reich, Kim A Papp, Christopher E M Griffiths, et al.The Journal of Dermatology|June 12, 2010
Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parametersManjula Reddy, Gisela Torres, Thomas McCormick, et al.Current Medical Research and Opinion|July 14, 2007
A multicenter, randomized, open study to evaluate the impact of an electronic data capture system on the care of patients with rheumatoid arthritisJoseph Huffstutter, W David Craig, Gregory Schimizzi, et al.Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Kim A Papp, Richard G Langley, Mark Lebwohl, et al.Journal of the American Academy of Dermatology|October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsKenneth B Gordon, Kim A Papp, Richard G Langley, et al.The New England Journal of Medicine|January 15, 2010
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasisChristopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, et al.Annals of the Rheumatic Diseases|April 7, 2007
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyDaniel E Furst, Norman Gaylis, Vance Bray, et al.Pageof 2